After the "Teva" and "Royalty Pharma" decisions of the CJEU, our attorney-at-law and managing partner Johannes Heselberger and our patent attorney and partner Dr. Axel B. Berger spoke about the applicable requirements for supplementary protection certificates and what they mean for SPC holders and third parties.
